Sophiris Bio, Inc.
SPHS
Other OTC0.00
USD
- -
- -
CIK
0001563855
ISIN
CA83578Q2099
CUSIP
83578Q209
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1258 Prospect Street La Jolla CA United States of America 92037
- IPO Date
- Nov 18, 2008
- CIK
- 0001563855
- Website
- sophirisbio.com
- Similar Companies
- Business
- Sophiris Bio Inc. (SPHS) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for urological diseases, including benign prostatic hyperplasia (BPH) and localized low- to intermediate-risk prostate cancer; its lead product candidate is topsalysin (PRX302), a recombinant pore-forming protein administered via targeted intraprostatic injection that selectively destroys prostate tissue upon activation by prostate-specific antigen, with additional pipeline candidate PRX124 under development for female stress urinary incontinence. Founded in 2002 and headquartered in La Jolla, California, the company previously operated as Protox Therapeutics Inc. before changing its name in April 2012; it holds strategic relationships with Kissei Pharmaceutical Co. Ltd. for development and commercialization in Japan and licenses core technology from UVIC Industry Partnerships Inc. and The Johns Hopkins University. Operations target North American and global markets through clinical trials and potential partnerships, with topsalysin having advanced through Phase IIb studies demonstrating durable symptom relief and favorable safety profiles in BPH and prostate cancer indications. In May 2020, Sophiris Bio announced the shutdown of operations after failing to secure funding or partners for topsalysin development despite extensive outreach to over 70 parties; no significant activity, funding rounds, acquisitions, or pipeline advancements have been reported since, with the company remaining inactive as of late 2025.
Wisr AI Systems Inc. Announces Closing of Amalgamation